$NVAX 1.48 0.00 0.00 61,156 1.54 1.57 Rem
Post# of 23064
(Total Views: 233)
Posted On: 07/24/2017 8:26:12 AM
$NVAX 1.48 0.00 0.00 61,156 1.54 1.57
Reminder: Novavax to Host an RSV F Vaccine Update Conference Call and Webcast on July 24, 2017 at 4:30 PM
2 days 22 hours 55 minutes ago - DJNF
-- Announce topline data from the Phase 2 Safety and Immunogenicity trial of the RSV F Vaccine in older adults
GAITHERSBURG, Md., July 21, 2017 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will host a conference call and webcast on Monday, July 24, 2017, at 4:30 p.m. ET. Novavax anticipates receiving results and announcing topline data from its Phase 2 safety and immunogenicity trial of the RSV F Vaccine in older adults (60 years of age and older). In addition, management will provide an update on its prior Phase 2 and Phase 3 clinical trials in older adults, as well as its RSV Phase 3 clinical trial for infants via maternal immunization, known as Prepare(TM), which continues to experience significant acceleration in enrollment and enhanced momentum heading into its third global season.
Preliminary webcast agenda:
1. Announce topline data from the Phase 2 safety and immunogenicity trial in
Older Adults
2. Provide additional findings from prior Phase 2 and Phase 3 clinical
trials in Older Adults
3. Update on the Prepare(TM) trial for Infants via Maternal Immunization
Conference call details are as follows:
Date: Monday, July 24, 2017
Time: 4:30 p.m. U.S. Eastern Time (ET)
Dial-in number: (877) 212-6076 (Domestic) or (707) 287-9331 (International)
Passcode: 54820069
Webcast: www.novavax.com, "Investors"/ "Events"
Conference call and webcast replay:
Starting at 7:30 p.m. ET, July 24, 2017, until 7:30 p.m. ET,
Dates: July 31, 2017
Dial-in number: (855) 859-2056 (Domestic) or (404) 537-3406 (International)
Passcode: 54820069
Webcast: www.novavax.com, "Investors"/ "Events", until October 24,
2017
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact:
Investor Relations
Novavax, Inc.
Andrea N. Flynn, Ph.D.
Director, Investor Relations
ir@novavax.com
240-268-2000
Westwicke Partners
John Woolford
john.woolford@westwicke.com
443-213-0506
Media
Russo Partners, LLC
David Schull
Maggie Beller
david.schull@russopartnersllc.com
maggie.beller@russopartnersllc.com
212-845-4271
View original content:http://www.prnewswire.com/news-releases/reminder-novavax-to-host-an-rsv-f-vaccine-update-conference-call-and-webcast-on-july-24-2017-at-430-pm-300492231.html
SOURCE Novavax, Inc.
/Web site: http://novavax.com
(END) Dow Jones Newswires
July 21, 2017 09:30 ET (13:30 GMT)
Reminder: Novavax to Host an RSV F Vaccine Update Conference Call and Webcast on July 24, 2017 at 4:30 PM
2 days 22 hours 55 minutes ago - DJNF
-- Announce topline data from the Phase 2 Safety and Immunogenicity trial of the RSV F Vaccine in older adults
GAITHERSBURG, Md., July 21, 2017 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will host a conference call and webcast on Monday, July 24, 2017, at 4:30 p.m. ET. Novavax anticipates receiving results and announcing topline data from its Phase 2 safety and immunogenicity trial of the RSV F Vaccine in older adults (60 years of age and older). In addition, management will provide an update on its prior Phase 2 and Phase 3 clinical trials in older adults, as well as its RSV Phase 3 clinical trial for infants via maternal immunization, known as Prepare(TM), which continues to experience significant acceleration in enrollment and enhanced momentum heading into its third global season.
Preliminary webcast agenda:
1. Announce topline data from the Phase 2 safety and immunogenicity trial in
Older Adults
2. Provide additional findings from prior Phase 2 and Phase 3 clinical
trials in Older Adults
3. Update on the Prepare(TM) trial for Infants via Maternal Immunization
Conference call details are as follows:
Date: Monday, July 24, 2017
Time: 4:30 p.m. U.S. Eastern Time (ET)
Dial-in number: (877) 212-6076 (Domestic) or (707) 287-9331 (International)
Passcode: 54820069
Webcast: www.novavax.com, "Investors"/ "Events"
Conference call and webcast replay:
Starting at 7:30 p.m. ET, July 24, 2017, until 7:30 p.m. ET,
Dates: July 31, 2017
Dial-in number: (855) 859-2056 (Domestic) or (404) 537-3406 (International)
Passcode: 54820069
Webcast: www.novavax.com, "Investors"/ "Events", until October 24,
2017
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact:
Investor Relations
Novavax, Inc.
Andrea N. Flynn, Ph.D.
Director, Investor Relations
ir@novavax.com
240-268-2000
Westwicke Partners
John Woolford
john.woolford@westwicke.com
443-213-0506
Media
Russo Partners, LLC
David Schull
Maggie Beller
david.schull@russopartnersllc.com
maggie.beller@russopartnersllc.com
212-845-4271
View original content:http://www.prnewswire.com/news-releases/reminder-novavax-to-host-an-rsv-f-vaccine-update-conference-call-and-webcast-on-july-24-2017-at-430-pm-300492231.html
SOURCE Novavax, Inc.
/Web site: http://novavax.com
(END) Dow Jones Newswires
July 21, 2017 09:30 ET (13:30 GMT)
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'